XENE

Xenon Pharmaceuticals Stock Analysis

AI Rating

Fair
  • Quality3/10
  • Growth↓ 0/10
  • Momentum↑ 6/10
Xenon Pharmaceuticals sales and earnings growth
XENE Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -37.94%
  • FCF Y/Y↓ -53.72%
Xenon Pharmaceuticals gross and profit margin trends
XENE Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4084.50%
  • ROIC↓ -55.80%
Xenon Pharmaceuticals net debt vs free cash flow
XENE Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Xenon Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗